Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs
NCT01271426 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74
Last updated 2011-01-06
Summary
To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.
Conditions
- Polypoidal Choroidal Vasculopathy
Sponsors & Collaborators
-
Nihon University
lead OTHER
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-04-30
- Primary Completion
- 2010-03-31
- Completion
- 2010-03-31
Countries
- Japan
More Related Trials
-
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
NCT01884597 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
NCT02806752 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
NCT00288561 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
NCT00284089 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
NCT01469156 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization
NCT03042871 ·Status: COMPLETED ·Phase: PHASE4
-
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
NCT01840410 ·Status: COMPLETED ·Phase: PHASE3
-
OCTA and Polypoidal Choroidal Vasculopathy
NCT04714242 ·Status: COMPLETED
-
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
NCT02484690 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
NCT06176352 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
NCT01810042 ·Status: COMPLETED ·Phase: PHASE4
-
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
NCT00363168 ·Status: COMPLETED ·Phase: PHASE1
-
Ranibizumab Treatment for Age-Related Macular Degeneretion
NCT02158624 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
NCT01217944 ·Status: COMPLETED ·Phase: PHASE3
-
Ranibizumab for Myopic Neovascularization
NCT01246089 ·Status: UNKNOWN ·Phase: PHASE4
-
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
NCT00749021 ·Status: COMPLETED ·Phase: PHASE1
-
The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)
NCT03159884 ·Status: UNKNOWN ·Phase: PHASE4
-
Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen
NCT01037348 ·Status: COMPLETED ·Phase: PHASE2
-
Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy
NCT01746563 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
NCT00500344 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
NCT00251459 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
NCT00674323 ·Status: COMPLETED ·Phase: PHASE4
-
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
NCT00457145 ·Status: COMPLETED ·Phase: PHASE1
-
Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging
NCT03105609 ·Status: TERMINATED
-
Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease
NCT00841373 ·Status: COMPLETED ·Phase: PHASE1/PHASE2